Copyright
©The Author(s) 2020.
World J Gastroenterol. Nov 7, 2020; 26(41): 6455-6474
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Published online Nov 7, 2020. doi: 10.3748/wjg.v26.i41.6455
Table 2 Unadjusted comparisons of the measured clinical outcomes, health resources utilization, and direct medical costs associated with infliximab maintenance therapy and conventional maintenance therapy during 1-year observation time
IMT, n = 295 | CMT, n = 130 | P value | |||||
Outcome measure | Mean/% | SD | Median | Mean/% | SD | Median | |
Clinical outcomes | |||||||
Surgery rate | 12.7% | 25.4% | 0.002b | ||||
Disease remission rate | 94.6% | 86.9% | 0.008b | ||||
Utility for quality of life | 0.890 | 0.080 | 0.900 | 0.757 | 0.093 | 0.748 | < 0.001 |
Newly developed complications | |||||||
Any complications | 27.0% | 42.3% | 0.002b | ||||
Anus fistula | 17.4% | 14.6% | 0.489 | ||||
Intestinal fistula | 3.5% | 4.6% | 0.582 | ||||
Intestinal obstruction | 4.2% | 12.3% | 0.003b | ||||
Perianal abscess | 5.8% | 6.2% | 0.886 | ||||
Bowel perforation | 1.9% | 3.8% | 0.260 | ||||
Health resource utilization | |||||||
Outpatient clinic visits | 1.9 | 3.3 | 1.0 | 3.7 | 5.2 | 2.0 | < 0.001 |
Hospital admissions | 5.3 | 2.2 | 6.0 | 1.4 | 1.0 | 1.0 | < 0.001 |
Hospital admissions for infliximab administration | 4.4 | 2.2 | 5.0 | 0.0 | 0.0 | 0.0 | < 0.001 |
Hospital admissions for active disease management | 0.9 | 1.0 | 1.0 | 1.4 | 1.0 | 1.0 | < 0.001 |
Hospital stay days | 15.2 | 11.1 | 14.0 | 14.8 | 12.4 | 9.5 | 0.207 |
Hospital stay days related to infliximab administration | 5.7 | 3.8 | 6.0 | 0.0 | 0.0 | 0.0 | < 0.001 |
Hospital stay days for active disease management | 9.5 | 11.3 | 9.0 | 14.8 | 12.4 | 9.5 | < 0.001 |
Direct medical costs for outpatient clinic visits | |||||||
Outpatient costs for drugs | ¥710 | ¥4,268 | ¥0 | ¥2,342 | ¥4698 | ¥644 | < 0.001 |
Outpatient costs for others | ¥232 | ¥589 | ¥0 | ¥130 | ¥446 | ¥0 | 0.008b |
Total outpatient costs | ¥942 | ¥4371 | ¥54 | ¥2473 | ¥4777 | ¥810 | < 0.001 |
Direct medical costs for hospitalizations | |||||||
Hospital costs related to infliximab administration | ¥5,305 | ¥7650 | ¥3577 | ¥0 | ¥0 | ¥0 | < 0.001 |
Drug acquisition costs of infliximab | ¥39018 | ¥9610 | ¥39200 | ¥0 | ¥0 | ¥0 | < 0.001 |
Hospital costs for active disease management | ¥11041 | ¥17982 | ¥4090 | ¥24274 | ¥29285 | ¥9321 | < 0.001 |
Total hospital costs | ¥55365 | ¥22337 | ¥52155 | ¥24274 | ¥29285 | ¥9321 | < 0.001 |
Total direct medical costs | ¥56307 | ¥23866 | ¥52476 | ¥26747 | ¥30541 | ¥12503 | < 0.001 |
- Citation: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474
- URL: https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i41.6455